3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Cyclophosphamide
6
Isotretinoin
5
thymoglobulin
4
fludarabine phosphate
4
fludarabine
4
aldesleukin
4
Topotecan
4
Temozolomide
4
Melphalan
4
Irinotecan
4
Etoposide
4
ribociclib
3
Thiotepa
3
Interleukin-2
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Busulfan
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
temsirolimus
2
omburtamab I-131
2
dinutuximab
2
Vincristine
2
Tretinoin
2
TPI-287
2
Stem Cell Transplantation
2
Rituximab
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neuroblastoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts